Athanor Capital, LP Macrogenics Inc Transaction History

Athanor Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $176,152 - $306,311	-8,597 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$18.99 - $33.2 $230,937 - $403,745	-12,161 Reduced 58.58%	8,597 $274,000
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $164,887 - $220,870	8,495 Added 69.27%	20,758 $475,000
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $302,773 - $387,510	12,263 New	12,263 $309,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.